CLSA’s latest Protect Access & Innovation piece highlights an LA Times article regarding insurance industry practices that limit patient access to care.
CLSA’s latest Protect Access & Innovation flyer calls attention to a recent op-ed in The Hill (“The man behind the curtain in drug price increases”) by Rep. Earl Carter, the only pharmacist serving in Congress, highlighting the roles that PBMs play in the drug pricing equation.
See the highlights from our 2017 California Life Sciences Industry Report. California leads the world in life sciences innovation. Premier research institutions combine with a unique entrepreneurial spirit to develop new technologies, attract investors and push the state’s economy to greater heights.
CLSA’s latest Protect Access & Innovation flyer calls attention to a recent “I Am Essential” patient advocate coalition letter, calling on HHS Secretary Sylvia Mathews Burwell to more aggressively enforce the Affordable Care Act’s prohibition on discriminatory treatment of patients, particularly those with chronic conditions.
The Feds are gunning for the biggest middle man in the American pharmaceutical game, Express Scripts, according to government filings published on Tuesday along with the company’s earnings.
The health law prohibits insurers from discriminating against people with serious illnesses, but some marketplace plans sidestep that taboo by making the drugs that people with HIV need unavailable or unaffordable, complaints filed recently with the Department of Health and Human Services’ Office for Civil Rights allege.
Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen. However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.
Are you registered to vote? If not, the LAST DAY to register to vote for the November election is Monday, October 24. Be sure to register if you aren’t already a registered voter.
The way we pay for medications is far more complex than a simple sound bite. It is an intricate chain as medicines wind their way from manufacturers to patients and their doctors. Healthcare middlemen like PBMs play a major role in overall healthcare costs, and can significantly add to the price of patient care.
Pretty darn bad. It is so bad that stalwart Republican and MSNBC Morning Joe host Joe Scarborough this week enthusiastically embraced Columbia professor and Earth Institute director Jeffrey Sachs’ views on the outrage of Gilead Sciences and its pricing of the breakthrough hepatitis C drugs Sovaldi and Harvoni.